Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

22.04.2024 - Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN (LX2006) to support regulatory discussions ... Seite 1

Related Keywords

, Cornell University , Lexeo Therapeutics Inc , Nasdaq , Weill Cornell Medicine , Cornell Medicine , Lexeo Therapeutics Regsitered Chart , Exeo Therapeutics Regsitered Kurs , Exeo Therapeutics Regsitered Aktie ,